Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis
暂无分享,去创建一个
N Freemantle | P Bebbington | N. Freemantle | J. Geddes | P. Bebbington | J Geddes | P Harrison | P. Harrison
[1] K. Wahlbeck,et al. Clozapine versus typical neuroleptic medication for schizophrenia. , 2000, The Cochrane database of systematic reviews.
[2] Leiyu Shi,et al. Health Services Research Methods , 1996 .
[3] Igor Sartori,et al. Empirical Evidence of Bias. Dimensions of Methodological Quality Associated with Estimates of Treatment Effects in Controlled Trials , 1996 .
[4] N. Laird,et al. Meta-analysis in clinical trials. , 1986, Controlled clinical trials.
[5] F. Song,et al. Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials. , 1997, Journal of psychopharmacology.
[6] J. Mason,et al. North of England evidence based guidelines development project: methods of developing guidelines for efficient drug use in primary care , 1998, BMJ.
[7] R. Tamura,et al. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol , 1999, British Journal of Psychiatry.
[8] L. Kirk,et al. [Treatment of schizophrenia]. , 1971, Ugeskrift for laeger.
[9] D. Kohen,et al. Atypical antipsychotics and neuroleptic malignant syndrome , 1999, British Journal of Psychiatry.
[10] S. Leucht,et al. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials , 1999, Schizophrenia Research.
[11] R. Kerwin. Atypical antipsychotics in the treatment of schizophrenia , 2001, BMJ : British Medical Journal.
[12] S. Lankappa,et al. Quetiapine for schizophrenia. , 2004, The Cochrane database of systematic reviews.
[13] R. J. Hayes,et al. Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. , 1995, JAMA.
[14] T. Hak,et al. Collusion in doctor-patient communication about imminent death: an ethnographic study , 2000, BMJ : British Medical Journal.
[15] J. Overall,et al. The Brief Psychiatric Rating Scale , 1962 .
[16] T. Chalmers,et al. Antipsychotic drugs: is more worse? a meta-analysis of the published randomized control trials , 1994, Psychological Medicine.
[17] S. Kay,et al. The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.
[18] M. Heo,et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. , 1999, The American journal of psychiatry.
[19] Fujian Song. Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials , 1997 .
[20] D J Spiegelhalter,et al. Bayesian approaches to random-effects meta-analysis: a comparative study. , 1995, Statistics in medicine.
[21] S. Gilbody,et al. Risperidone versus typical antipsychotic medication for schizophrenia. , 2000, The Cochrane database of systematic reviews.
[22] D M Steinwachs,et al. Patterns of usual care for schizophrenia: initial results from the Schizophrenia Patient Outcomes Research Team (PORT) Client Survey. , 1998, Schizophrenia bulletin.
[23] S. Woods. Olanzapine and tardive dyskinesia , 1999, British Journal of Psychiatry.